TVGN TEVOGEN BIO HOLDINGS INC

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston



WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025.

The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta will join industry peers including Chris Gervais, CTO of Codametrix, and Stavros Papadopoulos, CEO of TileDB, in a discussion moderated by Tony Pezzullo, Principal at SignalFire. Mehta will share perspectives on Tevogen.AI’s application of advanced data and AI technologies, including its PredicTcell™ platform, developed in collaboration with Microsoft and Databricks, to accelerate precision immunotherapy development.

Databricks DATA + AI World Tour will take place at the Sheraton Boston Hotel. For more information please contact,

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

A photo accompanying this announcement is available at



EN
10/09/2025

Underlying

TVGNTEVOGEN BIO HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum ...

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta ...

September 10, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product...

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections. The TVGN 116 cumulative 5-year top-line revenue forecast is es...

September 9, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Pro...

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first clinical-stage product from its proprietary ExacTcell™ platform. TVGN-489 is being developed for the treatment of SARS-CoV-2 infection in high-risk vulnerable patients and for Long-COVID in patie...

September 8, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipe...

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000 patients.Focused on improved prognosis for patients with hematologic malignancies. WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today shared asset value and potential forecast for the...

September 4, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Underscores the Importance of Precision Immunotherapies, Inclu...

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of complications from the virus. TVGN 489, the Company’s investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy is developed using the ExacTcell platform. It is designed to for...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch